Eton Pharmaceuticals Stock Today
| ETON Stock | USD 14.25 0.24 1.71% |
PerformanceInsignificant
| Odds Of DistressLow
|
Eton Pharmaceuticals is selling at 14.25 as of the 30th of June 2025; that is 1.71 percent increase since the beginning of the trading day. The stock's open price was 14.01. Eton Pharmaceuticals has less than a 16 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 10th of August 2023 and ending today, the 30th of June 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of November 2018 | Category Healthcare | Classification Health Care |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. Eton Pharmaceutcials operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 26.82 M outstanding shares of which 1.12 M shares are currently shorted by private and institutional investors with about 2.38 trading days to cover. More on Eton Pharmaceuticals
Moving against Eton Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Eton Stock Highlights
| CEO President | Sean Brynjelsen | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEton Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Eton Pharmaceuticals' financial leverage. It provides some insight into what part of Eton Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Eton Pharmaceuticals (ETON) is traded on NASDAQ Exchange in USA. It is located in 21925 W. Field Parkway, Deer Park, IL, United States, 60010-7278 and employs 31 people. Eton Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 376.73 M. Eton Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 26.82 M outstanding shares of which 1.12 M shares are currently shorted by private and institutional investors with about 2.38 trading days to cover.
Eton Pharmaceuticals currently holds about 17.05 M in cash with 969 K of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.67.
Check Eton Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationEton Pharmaceuticals holds a total of 26.82 Million outstanding shares. Over half of Eton Pharmaceuticals' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Eton Ownership Details
Eton Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2025-03-31 | 298.2 K | |
| Renaissance Technologies Corp | 2025-03-31 | 274 K | |
| Aristides Capital Llc | 2025-03-31 | 241.6 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2025-03-31 | 232.5 K | |
| Thompson, Siegel & Walmsley Llc | 2025-03-31 | 189.9 K | |
| Goldman Sachs Group Inc | 2025-03-31 | 175.2 K | |
| Springbok Capital Management, Llc | 2025-03-31 | 169.4 K | |
| Morgan Stanley - Brokerage Accounts | 2025-03-31 | 147.3 K | |
| Mink Brook Asset Management Llc | 2025-03-31 | 141.5 K | |
| Opaleye Management Inc | 2025-03-31 | 2.9 M | |
| Ecor1 Capital, Llc | 2025-03-31 | 1.9 M |
Eton Pharmaceuticals Historical Income Statement
Eton Stock Against Markets
Eton Pharmaceuticals Corporate Management
| Danka Radosavljevic | Executive Operations | Profile | |
| James CPA | Treasurer CFO | Profile | |
| Kevin Guthrie | Executive Operations | Profile | |
| Scott Grossenbach | Senior Operations | Profile | |
| Ingrid Hoos | Senior Affairs | Profile | |
| Ipek ErdoganTrinkaus | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share (0.18) | Revenue Per Share 1.846 | Quarterly Revenue Growth 1.169 | Return On Assets (0.02) |
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.